TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03967379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App + enhanced standard care
Description: An intervention to help address sexual dysfunction among HCT survivors

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Standard Care
Description: Standard of care administered by the institution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Standard Care
Description: Standard of care administered by the institution
Study: NCT02101515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Length of Second Stage
Description: The experimental group will have one additional hour in the second stage of labor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Length of Second Stage
Description: The experimental group will have one additional hour in the second stage of labor
Study: NCT01095367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seprafilm™
Description: Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort.
Study: NCT02218190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05709236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary screw-retained prosthesis
Description: Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary screw-retained prosthesis
Description: Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
Study: NCT03508167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Band
Description: Thermal Band used 8 hours per day

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermal Band
Description: Thermal Band used 8 hours per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorilax®
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.
Study: NCT06425276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride for Injection
Description: During the Study Period, patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2.
Study: NCT01613495

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
Study: NCT02765620

Intervention type: OTHER
Intervention: drug&radiation
Description: 1. Early treatment response assessment: using baseline data and early follow-up data~2. Evaluate treatment response: using baseline data, early follow-up data and final data~3. Compare PERCIST to RECIST criteria: correlation analysis~4. Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)

Intervention type: OTHER
Intervention: drug&radiation
Description: 1. Early treatment response assessment: using baseline data and early follow-up data~2. Evaluate treatment response: using baseline data, early follow-up data and final data~3. Compare PERCIST to RECIST criteria: correlation analysis~4. Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)
Study: NCT04061551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC clinic support - whole of practice interventions delivery through nurse-led model
Description: The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~* Patient support to reduce the impact of hepatitis C and other blood borne viruses~* Provider support to reduce the impact of hepatitis C and other blood borne viruses~* Practice support to reduce the impact of hepatitis C and other blood borne viruses
Study: NCT02802930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y65 110 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y51 002 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 V27 104 (BAY987519)
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride [NaCl]
Description: Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
Study: NCT02910765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Study: NCT00526396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 80 mg/m2 on day 1 for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 100 mg/m2 on days 1,2,3 for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
Study: NCT00437671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetanus Immune Globulin (Human)
Description: Based on package insert recommendation and recommendations of WHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria-Tetanus Toxoids Adsorbed
Description: Based on package insert recommendations and recommendations of WHO
Study: NCT00775736

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

Intervention type: DRUG
Intervention: biphasic insulin aspart 50
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice

Intervention type: DRUG
Intervention: biphasic insulin aspart 70
Description: Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
Study: NCT03661944

Intervention type: DIAGNOSTIC_TEST
Intervention: functional performance test
Description: Functional performance test is to test the ability of the athletes in functional movements

Intervention type: DIAGNOSTIC_TEST
Intervention: functional performance test
Description: Functional performance test is to test the ability of the athletes in functional movements
Study: NCT00247936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Esophagectomy
Description: Laparoscopic Esophagectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Esophagectomy
Description: Laparoscopic Esophagectomy
Study: NCT01892514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression
Description: core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression
Description: core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
Study: NCT03652259

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-9003
Description: SRP-9003 will be administered through a single systemic injection.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-9003
Description: SRP-9003 will be administered through a single systemic injection.
Study: NCT03986866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
Study: NCT03575455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: HR-controlled treadmill walking
Study: NCT00800423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.2%
Description: Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate 0.5%
Description: timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye
Study: NCT04134364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alginate
Description: 3 days oral administration of sodium alginate after gastric biopsy
Study: NCT03511547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pitch Patch
Description: The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ \[PP\]) augmentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArthroFlex
Description: The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® \[AF\]) augmentation.
Study: NCT03920813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
Study: NCT00935545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide
Description: Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
Study: NCT01375335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: 90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
Study: NCT02003014

Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone Tablets
Study: NCT01765283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaStem
Study: NCT00685191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvage antiretroviral therapy including raltegravir
Description: Initiation of raltegravir-including salvage antiretroviral therapy
Study: NCT03785678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
Study: NCT01660451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on.
Study: NCT06026683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implant
Description: Implantation of pacemaker with conduction system pacing or right ventricular apical pacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implant
Description: Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
Study: NCT02960373

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Bread (Control)
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried Fruit - Glycemic Index
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catalytic Fructose Dose Effect
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Displacement Effect
Description: A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
Study: NCT02849158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Rectoscopy with biopsy
Study: NCT02231788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telminuvo®Tab. 40/2.5mg
Description: Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmitrend®Tab. 80mg
Description: Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
Study: NCT02536755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat, GZ385660
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT01699854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capsaicin patch (qutenza)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03247426

Intervention type: OTHER
Intervention: Evaluation individuals
Description: Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.

Intervention type: OTHER
Intervention: Evaluation individuals
Description: Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
Study: NCT03445260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplements
Description: PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
Study: NCT04643314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided video-based self-evaluation
Description: In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure.
Study: NCT02322229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 0.125 mg in a 0.1 mL volume
Study: NCT00609843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipiodol demarcation of the bladder tumour
Description: 1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
Study: NCT00581685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin, Celecoxib
Description: Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
Study: NCT04382196

Intervention type: OTHER
Intervention: Online survey
Description: An online survey will be administered
Study: NCT02345304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study: NCT04243603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)
Description: Please see description of experimental arm (arm one)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)
Description: Please see description of experimental arm (arm one)